erlotinib hydrochloride has been researched along with cystamine in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (cystamine) | Trials (cystamine) | Recent Studies (post-2010) (cystamine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 1,294 | 4 | 174 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tan, S; Wang, G | 1 |
1 other study(ies) available for erlotinib hydrochloride and cystamine
| Article | Year |
|---|---|
Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo.
Topics: Acrylic Resins; Animals; Antineoplastic Agents; Cell Proliferation; Cystamine; Drug Delivery Systems; Drug Stability; Erlotinib Hydrochloride; Humans; Hydrogen-Ion Concentration; Lipids; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Nanoparticles; Neoplasms, Experimental; Oleic Acid; Oxidation-Reduction; Particle Size; Tumor Cells, Cultured | 2017 |